I have been thinking long and hard regarding the progress on the pill formulation for Kevetrin as a company PR about May '17 said it should be ready to test on healthy people around Jan '18.
Since this test would not be a trial as there are no patients with any conditions to cure, the drug has already proved itself safe at the dosage they will have in the formulation (doubt if it would be above 800 units), and the only information they need to gather are the physio kinetic (or whatever the proper term is for seeing how fast the drug leaves the body) properties of the formulation, could the company test it on a number of healthy people in conjunction with a recognized medical dept. so that the data could be presented to the FDA so that K could go back for a quick P2b trial with the pill?
Just hard to believe company hasn't been able to go the last few yards into the end zone on this matter as it appeared they were pretty sure they had it licked middle of last year.
Since this test would not be a trial as there are no patients with any conditions to cure, the drug has already proved itself safe at the dosage they will have in the formulation (doubt if it would be above 800 units), and the only information they need to gather are the physio kinetic (or whatever the proper term is for seeing how fast the drug leaves the body) properties of the formulation, could the company test it on a number of healthy people in conjunction with a recognized medical dept. so that the data could be presented to the FDA so that K could go back for a quick P2b trial with the pill?
Just hard to believe company hasn't been able to go the last few yards into the end zone on this matter as it appeared they were pretty sure they had it licked middle of last year.
